Biomarkers in Patients With Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01138319
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : May 6, 2015
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in patients with acute myeloid leukemia.

Condition or disease Intervention/treatment
Leukemia Genetic: DNA analysis Genetic: mutation analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis

Detailed Description:


  • To determine whether clonally expanded somatic mitochondrial DNA mutations are associated with acute myeloid leukemia.

OUTLINE: Genomic DNA from blood samples obtained at diagnosis, remission, and relapse are analyzed for mitochondrial DNA mutations via PCR.

Study Type : Observational
Actual Enrollment : 18 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Mitochondrial Mutations and AML
Study Start Date : February 2009
Actual Primary Completion Date : March 2010

Primary Outcome Measures :
  1. Association between clonally expanded somatic mitochondrial DNA mutations and acute myeloid leukemia

Biospecimen Retention:   Samples With DNA
blood samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosis of acute myeloid leukemia


  • Diagnosis of acute myeloid leukemia
  • Available blood samples from diagnosis, remission, and relapse


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01138319

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Jason H. Bielas, PhD Fred Hutchinson Cancer Research Center

Responsible Party: Children's Oncology Group Identifier: NCT01138319     History of Changes
Other Study ID Numbers: AAML10B6
COG-AAML10B6 ( Other Identifier: Children's Oncology Group )
CDR0000671467 ( Other Identifier: Clinical )
NCI-2011-02224 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
First Posted: June 7, 2010    Key Record Dates
Last Update Posted: May 6, 2015
Last Verified: May 2015

Keywords provided by Children's Oncology Group:
adult acute myeloid leukemia
childhood acute myeloid leukemia/other myeloid malignancies

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type